A comprehensive view of Valneva SE. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer investing US$95M in vaccine company Valneva SE; investment supports strategic partnership between both companies to develop Lyme disease vaccine

Valneva, Pfizer report positive Phase 2 pediatric data for VLA15 Lyme disease vaccine candidate; VLA15 is the only Lyme disease vaccine currently in clinical development, with Lyme disease affecting 476,000 people in US, 130,000 people in Europe annually

Valneva Scotland announces research funding of up to £20M from Scotland’s national economic development agency; initial grant of £12.5M supports development related to Valneva’s inactivated, whole virus COVID-19 vaccine candidate

Valneva announces its inactivated COVID-19 vaccine candidate neutralizes Omicron variant in Phase 1/2 trial; 100% of participants showed antibodies against ancestral virus and Delta variant, 87% had antibodies against Omicron

Valneva announces advance purchase agreement with the European Commission to supply up to 60 million doses of inactivated COVID-19 vaccine candidate over two years; company expects to deliver 24.3 million doses during Q2 and Q3 of 2022

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count